NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Collection of Blood from Patients with Prostate Cancer

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

07-C-0100

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male
Min Age: 18 Years
Max Age: N/A

Referral Letter Required

Yes

Population Exclusion(s)

Children

Keywords

Genetic;
Prostatic Neoplasms;
Genotyping;
Venipuncture;
Polymorphism;
Natural History

Recruitment Keyword(s)

Prostate Cancer

Condition(s)

Cancer Of Prostate;
Prostate Cancer;
Prostatic Neoplasms;
Metastatic Prostate Cancer;
Prostate

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Cancer Institute

Background:

-It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays an important role.

-Genes contain the hereditary information that is passed down from parents to children. Although everyone has the same set of genes, individuals can have different forms of the same gene.

-Differences in genes may explain, at least in part, why some people develop a more aggressive form of prostate cancer than others.

Objectives:

-To obtain blood samples from patients with prostate cancer to try to identify gene differences associated with progression to the androgen independent state.

Eligibility:

-All participants participating in NCI prostate cancer protocols.

Design:

-Participants with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.

-Blood samples are collected at the initial visit or at follow-up visits.

-DNA (genetic material) and white blood cells are extracted from these samples to be used for genotyping and establishment of cell lines.

-Gene variations are correlated with prostate cancer prognosis and prognostic indicators.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

Patients 18 years of age and older are eligible.

Patients with a diagnosis of prostate cancer are eligible.

EXCLUSION CRITERIA:

Children are not eligible.


--Back to Top--

Citations:

Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM Jr, Bueschen AJ, Lowe BA. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med. 1998 Oct 8;339(15):1036-42.

Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985 Jun;3(6):827-41.

Ruijter E, van de Kaa C, Miller G, Ruiter D, Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr Rev. 1999 Feb;20(1):22-45.

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

William D. Figg, Pharm.D.
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 5A01
10 Center Drive
Bethesda, Maryland 20892
(240) 760-6179
figgw@mail.nih.gov

Paula A. Carter, R.N.
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 4B11
10 Center Drive
Bethesda, Maryland 20892
(240) 858-3191
pcartera@mail.nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937

Clinical Trials Number:

NCT00923221

--Back to Top--